Cenduit Launches New Release of IRT Platform; Includes Direct-to-Patient with Seamless Integration, Exclusive Labeling Capabilities, Powerful Audit Trail Extract


New performance and scalability enhancements deliver quality, innovation and experience biopharma demands to build large, increasingly complex, patient-focused clinical studies

October 11, 2018 – Durham, NC – Cenduit LLC announced the newest release of the Cenduit IRT (CIRT) platform, with enhancements including the ability to build direct-to-patient clinical studies. CIRT combines faster study set-up with the flexibility of customization, regardless of study complexity. CIRT builds efficient, cost effective and safe clinical studies that simplify life for sites and patients.

Cenduit’s unique new Direct-to-Patient Virtual Trials technology expands the possibilities for conducting remote trials with direct integration into the CIRT platform. Cenduit Enterprise Architect Chris Driver explained, “The adoption of connected devices and mobile platforms is growing as biopharma seeks ways to conduct remote trials. Virtual Trials opens up a potentially massive global patient population by bringing trials directly to patients. Our technology advancements continue breaking new ground, effectively partnering with our clients to support siteless trials.”

Key new features of CIRT include:

●       Relabeling Enhancements – Streamlined capabilities and a more simplified process demonstrate Cenduit’s continuing investment in its drug management platform to streamline relabeling, particularly for emerging biopharma. CIRT helps clients save time and resources by creating a one-step approval process for the expiry date and affected countries. Clients also can improve management of overlapping expiry dates, with full control over when to lock or unlock a campaign.

●       Audit Trail Extract – Consequences can be severe if a sponsor or CRO is unable to answer audit-related questions. A failed site audit can result in expensive delays, non-approval of the investigational drug, and/or potential liabilities. The new Audit Trail Extract tool responds immediately to a client or auditor request by automatically extracting audit trails for any study.

Cenduit Chief Executive Officer Sam Osman commented, “In 2019, clinical trials will become even more complex. We continue enhancing our agile technology to help sponsors and site users make changes quickly, whether via self-service tools or other innovations in our platform. Our goal as always, is to anticipate and respond to requests quickly, listening to the needs of sponsors and sites.”

The new CIRT release also offers enhancements to support large studies, and reporting on performance metrics and audit logs.

About Cenduit LLC

Cenduit enables clinical study sponsors and CROs to safely, quickly and economically deliver new drugs and therapies that improve and save lives. As the world leader in quality IRT systems, Cenduit accelerates study startup, with clinical supply chain intelligence, deep clinical operations expertise and client-centric CORE teams. With 500+ experts throughout the US, Europe and Asia, Cenduit helps customers manage clinical studies in over 100 countries, interacting with nearly 1,000,000 patients at over 32,000 sites. Visit www.cenduit.com for more information.



Shannon L. Davies, Shannon.lappindavies@cenduit.com, +1 919-998-3393

Brenda Nashawaty, brenda@nashawaty.com, +1 617-688-3253

IRT, Quantum InteractiveCenduit